Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2018-12-18 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, CSPC Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It references specific listing rules from the Hong Kong Stock Exchange and provides detailed information on share repurchases and issued shares. The content focuses on reporting changes in share capital and share buybacks, which aligns with announcements regarding share repurchase or issuance activities. The document is about disclosing capital changes rather than a full financial report or earnings release. Therefore, it fits best under the category of Transaction in Own Shares (POS). The document length is over 6000 characters and contains detailed data, confirming it is not a mere announcement but a disclosure report of share transactions by the company itself.
2018-12-18 English
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding a product licensing and commercialization agreement with another company. It details the terms of the agreement, including payments and rights granted. The document is relatively short (3,584 characters) and is an announcement of a business transaction rather than a financial report or regulatory filing. It does not contain financial statements, audit information, management changes, or voting results. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement impacting the company's commercial and financial position.
2018-12-17 English
PROGRESS UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF CSPC XNW GROUP ON THE SHENZHEN STOCK EXCHANGE
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding a progress update on the proposed spin-off and separate listing of CSPC XNW Group on the Shenzhen Stock Exchange. It references a previous announcement and regulatory review by the CSRC Public Offering Review Committee. The text explicitly states it is an announcement and includes cautionary advice to shareholders and investors. The document length is 3218 characters, which is relatively short and typical for an announcement rather than a full report. There are no financial statements or detailed financial data included, nor is this a transcript, report, or proxy material. The content is about an update on a capital market transaction (spin-off and listing), which fits best under Capital/Financing Update (CAP). It is not a report publication announcement or regulatory filing as it contains substantive update information rather than just a notice of report availability. Therefore, the classification is Capital/Financing Update (CAP).
2018-12-11 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a disclosure return related to changes in issued share capital and share buybacks by CSPC Pharmaceutical Group Limited. It includes detailed information about share repurchases, number of shares involved, prices paid, and compliance with listing rules. The document is a regulatory disclosure about share repurchase activity rather than a financial report or announcement of a report. It fits the description of a Transaction in Own Shares (POS) filing, which reports the company's buyback of its own shares.
2018-12-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 November 2018
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and securities movements rather than financial performance, management commentary, or regulatory certifications. It is a regulatory filing reporting monthly share capital movements, not a full financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-12-03 English
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR THE GROUP'S "AMOXICILLIN CAPSULES"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the passing of a regulatory consistency evaluation for their Amoxicillin Capsules. It is an announcement about a regulatory approval related to product quality and efficacy, not a financial report, management change, or shareholder meeting material. The document is short (2549 characters) and serves as a public disclosure of a regulatory milestone. It does not contain financial data, management discussion, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-11-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.